Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Part of paid clinical trials in Tucson, Arizona.

Sponsor
OSI Pharmaceuticals
Study ID
NCT00033241
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with gemcitabine may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining erlotinib with gemcitabine in treating patients who have newly diagnosed locally advanced or metastatic pancreatic cancer or other solid tumors.

Key Dates

First listed
Jan 27, 2003
Start date
Jul 23, 2001
Status verified
Jun 2015
Primary completion
Apr 22, 2004
Completion
Apr 22, 2004

Study Design

Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Arizona Cancer Center at University of Arizona Health Sciences CenterTucsonArizona85724-
Cancer Therapy and Research CenterSan AntonioTexas78229-3271-

Find similar trials in Tucson, AZ

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Arizona Cancer Center at University of Arizona Health Sciences Center· Tucson, AZCancer Therapy and Research Center· San Antonio, TX

Related Studies